I think if they can take care of the CR shortfall before the end of the month plus have a solid investor partner to take this up i see this as our next short term catalyst.
I cant see us going alone through to approval, i would see it as a huge risk if we went along with shoestring budget mindset we have today to implement and market a product like this - id hope for large pharma partnership or TO in the next 18 months
ANP Price at posting:
20.0¢ Sentiment: Buy Disclosure: Held
